Redhill Biopharma
RDHL
53 hedge funds and large institutions have $24.5M invested in Redhill Biopharma in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 15 increasing their positions, 11 reducing their positions, and 9 closing their positions.
133% more call options, than puts
Call options by funds: $4.3M | Put options by funds: $1.84M
67% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 9
36% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 11
10% more funds holding
Funds holding: 48 → 53 (+5)
0% less ownership
Funds ownership: 0% → 0% (-0%)
50% less capital invested
Capital invested by funds: $49.1M → $24.5M (-$24.6M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
+$522K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$461K |
| 3 |
GS
Gagnon Securities
New York
|
+$332K |
| 4 |
JP Morgan Chase
New York
|
+$298K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$271K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$5.21M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$3.14M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.34M |
| 4 |
II
Ibex Investors
Denver,
Colorado
|
-$1.74M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.22M |
RDHL Hedge Fund Activity: Q3 2021 in Review
53 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q3 2021, worth a combined $24.5M — down 50% from $49.1M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new RDHL positions and 9 closed out — a net gain of 6 holders — while 15 added to existing stakes and 11 trimmed.
The largest buyer was Envestnet Asset Management, opening a new position worth an estimated $522K. The largest seller was ARK Investment Management, cutting an estimated $5.21M.
- 53 institutional investors held Redhill Biopharma (RDHL) as of Q3 2021, up from 48 in Q2 2021.
- Funds reported $24.5M of Redhill Biopharma stock for Q3 2021, down 50% quarter-over-quarter.
- 15 funds opened new Redhill Biopharma positions in Q3 2021 and 9 closed out, a net change of +6 holders.
- The largest Redhill Biopharma buyer in Q3 2021 was Envestnet Asset Management, an estimated $522K added.
- The largest Redhill Biopharma seller in Q3 2021 was ARK Investment Management, an estimated $5.21M sold.
Based on aggregated 13F filings for Q3 2021.